Status:
UNKNOWN
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Lead Sponsor:
Huashan Hospital
Conditions:
Acromegaly
Cardiomyopathies
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is...
Eligibility Criteria
Inclusion
- patients with pituitary GH adenomas confirmed by surgery
- active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs
Exclusion
- patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP\>150mmHg or DBP\>95mmHg patients with contraindications to MRI
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04520646
Start Date
September 1 2020
End Date
August 31 2022
Last Update
August 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, Shanghai Municipality, China, 200040